Navigation Links
Dyspnea in Medical News

Perforomist Inhalation Solution data to be presented today at American Thoracic Society conference

... resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue medication use ... significant improvements in pulmonary function, dyspnea and rescue medication use were seen over ... was measured by serial spirometry, transitional dyspnea index (TDI), rescue albuterol use and the St. ...

Perforomist(R) Inhalation Solution Data in Patients With Moderate to Severe COPD to Be Presented at the International Conference of the American Thoracic Society

... resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue medication use ... significant improvements in pulmonary function, dyspnea and rescue medication use were seen over ... was measured by serial spirometry, transitional dyspnea index (TDI), rescue albuterol use and the St. ...

Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer

... cardiac ischemia (3 vs 1); anorexia (5 vs 8); dyspnea (18 vs 26); and chest pain (7 vs 8). The most ... (20 vs 23); edema (19 vs 24); dyspnea (72 vs 74); chest pain (38 vs ... (28 vs 9); diarrhea (26 vs 16); dyspnea (66 vs 62); chest pain (40 vs 30); and rash (22 ...

Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD

... Fumarate to Tiotropium Treatment Relieves dyspnea and Symptoms in COPD Patients in a poster session ... were measured by the baseline/transitional dyspnea index, daily recording of COPD symptoms, rescue ... significance between the mean transitional dyspnea index scores in the Perforomist/TIO and ...

ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)

... 3); cardiac ischemia (3 vs 1); anorexia (5 vs 8); dyspnea (18 vs 26); and chest pain (7 vs 8). The most ... (20 vs 23); edema (19 vs 24); dyspnea (72 vs 74); chest pain (38 vs ... (28 vs 9); diarrhea (26 vs 16); dyspnea (66 vs 62); chest pain (40 vs 30); and rash (22 ...

Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia

... use of oxygen to relieve day-to-day dyspnea in patients with COPD without resting hypoxemia. ... in the walk test, but no improvement in their dyspnea scores or on their questionnaires. When assessed ... controls, four patients showed improvement in the dyspnea scores with oxygen, and only one was identified ...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

... (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), ... (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). For more information about VELCADE ...

New research about chronic lung disease presented at CHEST 2008

... with American ginseng for fatigue, morphine sulfate for control of severe dyspnea and pain, licorice root powder for control of severe coughing spells, and ... used as nebulizer in two patients, was effective in the control of marked dyspnea and pain. One patient lived 4 months using the supportive therapy, while ...

New critical care research presented at CHEST 2008

... with American ginseng for fatigue, morphine sulfate for control of severe dyspnea and pain, licorice root powder for control of severe coughing spells, and ... used as nebulizer in two patients, was effective in the control of marked dyspnea and pain. One patient lived 4 months using the supportive therapy, while ...

CHEST 2008: Featured abstracts

... with American ginseng for fatigue, morphine sulfate for control of severe dyspnea and pain, licorice root powder for control of severe coughing spells, and ... used as nebulizer in two patients, was effective in the control of marked dyspnea and pain. One patient lived 4 months using the supportive therapy, while ...

More>>

Dyspnea in Medical Technology

Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables

... patient characteristics, early improvement in dyspnea (breathlessness) to day five, ... rapid, substantial and sustained relief from dyspnea (breathlessness). Relaxin also demonstrated ... for the study presented to the hospital with dyspnea due to AHF and with normal or elevated blood ...

Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure

... rapid, substantial and sustained relief from dyspnea (breathlessness). Relaxin also demonstrated ... use of relaxin led to considerable improvement in dyspnea when compared to placebo and lasted up to 14 ... for the study presented to the hospital with dyspnea due to AHF and with normal or elevated blood ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). In the ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). In the ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). In the ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain ...

Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI

... and end of each two-week period, the transition dyspnea index, and a treatment satisfaction/preference survey. In this trial, baseline dyspnea index results at Day 1 were similar between ... age, gender and severity subgroups. Transition dyspnea index results at Day 14 indicated that two weeks ...

Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone

... Fumarate to Tiotropium Treatment Relieves dyspnea and Symptoms in COPD Patients" in a poster ... were measured by the baseline/transitional dyspnea index, daily recording of COPD symptoms, rescue ... significance between the mean transitional dyspnea index scores in the Perforomist(TM)/TIO ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... (6%); nausea (12%); vomiting (11%); dyspnea (11%); and chest pain (9%). The most ... (3%); cardiac ischemia (3%); anorexia (5%); dyspnea (18%); and chest pain (7%). The most ... diarrhea (21%); stomatitis/pharyngitis (20%); dyspnea (72%); chest pain (38%); neuropathy/sensory ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), ... (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). About Multiple Myeloma Multiple ...

New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)

... if the diarrhea becomes severe. Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their physician. In clinical trials of AMITIZA (24 mcg) in ...

More>>

Dyspnea in Medical Dictionary

Dyspnea

... Names : Difficulty Breathing - First Aid, dyspnea - First Aid, Shortness of Breath - First Aid ... associated with difficulty breathing : ... dyspnea and Cough ing in Patients With Advanced Cancer ... Pericardial Effusion ... HAPE leads to dyspnea (shortness of breath), cough , tachycardia ...

Dysphagia

... Dysphonia ( Hoarseness or Changing Voice) dyspnea ( Breathing Difficulty ) Dyssomnia ( Sleeping ... di stress characterized by drooling , dyspnea (difficulty breathing ), tachypnea (fast ... drug . Dysphagia Difficulty in swallowing. dyspnea Difficult or painful breathing ; shortness of ...

Arthralgia

... that characterizes arthritis . Signs and symptoms of ricin inhalation include the acute onset of fever , chest tightness, cough , dyspnea , nausea , and arthralgia ( joint pain ) occurs 4 to 8 hours after inhalational exposure. Women on letrozole had significantly more hot ...

Asymptomatic

... is often an asymptomatic condition but it may be marked by mitral regurgitation with symptoms (as chest pain , fatigue , dizziness , dyspnea , or palpitations ) with a tendency in some cases to endocarditis or ventricular ... ENTERO VIRUS - A Picorna virus , small, single-stranded ...

Breathing

... of oxygen . Drug resistance The result of cells' ability to resist the effects of a specific drug . Dysphagia Difficulty in swallowing. dyspnea Difficult or painful breathing ; shortness of breath. Dysuria Difficult or painful urination . E ... As the inflammation spreads up the ...

Chest pain

... chest pain that feels like a strangling or heavy pressure on the chest ... chest pain fever cough difficult or labor ed breathing ( dyspnea ) The symptoms of mediastinal cysts and tumor s may resemble other problems or medical conditions. Always consult your child's physician for a ...

Choking

... cause serious injury . Do not perform CPR unless: ... See first aid for choking . Alternative Names: Difficulty breathing - first aid; dyspnea - first aid; Shortness of breath - first aid Considerations: ... Cut the food into small pieces to prevent choking . Avoid food that ...

Dental injuries

... Difficulty Breathing ( First Aid for Difficulty Breathing ) Dislocated Jaw (Broken OR Dislocated Jaw ) Dislocated Elbow in Children dyspnea ( First Aid for Difficulty Breathing ) Electrical Shock ( Electrical Injury ) Electrical Injury ... The following are some suggestions to ...

Diaphragm

... vagina during intercourse in order to prevent pregnancy . Diaphragm atic Spasm s ( Hiccups ) Difficulty Breathing (Shortness of Breath) dyspnea (Shortness of Breath) Hiccups Noisy Breathing in Adults Noisy Breathing in Children Shortness of Breath SOB (Shortness of Breath) ... ...

Dislocated elbow

... - Disorganized (Hebephrenic)) Disseminated Gonococcal Infection (DGI) ( Gonococcal Arthritis ) ... Dislocated Elbow in Children dyspnea ( First Aid for Difficulty Breathing ) Electrical Shock ( Electrical Injury ) Electrical Injury Epilepsy ( Seizure ) Eye Emergencies ...

More>>

Dyspnea in Biological News

Franklin Square to study airway bypass procedure for severe emphysema

... are supported and kept open by Exhale Drug-Eluting Stents manufactured by Broncus Technologies, Inc. Patients could see an immediate improvement in dyspnea (shortness of breath). "We are excited to be part of this study because currently there are limited treatment options for emphysema. Patients are ...

Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema

... Stent manufactured by Broncus Technologies, Inc. - to allow the trapped air in the lung to escape. Patients could see an immediate improvement in dyspnea (shortness of breath). The airway bypass procedure could be an excellent option for those who may be considering lung transplant or who may not be ...

Positive results for airway bypass

... in RV over baseline at 6 months (p=0.04). Patients also showed a statistically significant improvement in the modified Medical Research Council dyspnea Scale (mMRC), a breathlessness test, of -0.5 points (p= 0.025). Retrospective analysis revealed that patients with the most severe hyperinflation of ...

Extra-aggressive form of idiopathic pulmonary fibrosis identified

... and progressive lung disorder from which most patients die within 5 years after diagnosis. The disease is characterized by the insidious onset of dyspnea or cough and usually evolves slowly. Now, Selman and coworkers present in an article published in the online, open-access journal PLoS ONE on ...

Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

... (low white blood cell counts). Other side effects were considered mild to moderate and included nausea, fatigue, dehydration, arthralgias, dyspnea and neuropathy. None of the patients discontinued the study due to hematological toxicity. "The results from this study with E7389 appear ...
Dyspnea in Biological Technology

AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women

... if the diarrhea becomes severe. Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their physician. In clinical trials of AMITIZA (24 mcg) in ...

FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

... (24%), skin rash (22%), nausea (22%), hemorrhage (21%), fatigue (21%), and dyspnea (20%). The most frequently reported serious adverse reactions included ... infection (2%), febrile neutropenia (4%), gastrointestinal bleeding (4%), dyspnea (3%), sepsis (1%), diarrhea (2%), congestive heart failure (2%), and ...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

... increase in 6-month survival compared to the docetaxel plus placebo arm. Common adverse events included fatigue (18 percent), anemia (18 percent) and dyspnea (18 percent). Using NSCLC cell lines, a genomic profile predicting response to AT-101 was developed in collaboration with Duke University . ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... (40% vs 51%), fever (21% vs 31%), nausea (46% vs 63%), stomatitis (41% vs 15%), vomiting (33% vs 44%), diarrhea (21% vs 35%), anorexia (20% vs 22%), dyspnea (15% vs 23%), HFS (51% vs 1%), and rash (29% vs 12%) In addition, 19% vs 52.3% reported alopecia (all grades) Grade 3/4 ...

Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA

... is a novel chimeric natriuretic peptide in clinical development for the treatment of acute heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. The Company believes that the ...

University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System

... patient functional capacity, monitoring their response to therapy and predicting outcome. Shape-HF™ is designed to quantify the severity of dyspnea on exertion and fatigue and evaluate the interaction between the heart, lungs, and other organ systems. This makes it possible for the physician to ...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

... assessment of absolute change from Baseline to Week 72 in percent predicted FVC 4. Change from Baseline to Week 72 in dyspnea measured by the University of California at San Diego Shortness-of-Breath Questionnaire (UCSD SOBQ) 5. Change from ...

Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium

... or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. The primary manifestations of heart failure are dyspnea and fatigue, which may limit exercise tolerance, result in fluid retention, and lead to pulmonary congestion and peripheral edema. These ...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

... pain (59%), and pain-other (51%). The most common grade 3/4 adverse events (greater than or equal to 10%) included: fatigue (33%), pain-other (16%), dyspnea (16%), abdominal pain (14%), infection without neutropenia (13%), rash/desquamation (12%), and other-gastrointestinal (10%) -- The most frequent ...

Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure

... or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. The primary manifestations of heart failure are dyspnea and fatigue, which may limit exercise tolerance, result in fluid retention, and lead to pulmonary congestion and peripheral edema. These ...
Other Contents
(Date:12/24/2014)... 24, 2014 Attorneys handling talcum powder ... update to their website, the Talcum Powder Ovarian ... talcum powder class action lawsuits and ovarian cancer claims. ... ovarian cancer updates at their website, which serves as ... ovarian cancer claims are not the same as class ...
(Date:12/24/2014)... Final Cut Pro X plugin ... Film Studios. , “The ProDenoise plugin that allows users to ... said Christina Austin, CEO of Pixel Film Studios. “ProDenoise is ... X editors toolbox.” , Final Cut Pro X users can ... footage with ProDenoise from Pixel Film Studios. ProDenoise can quickly ...
(Date:12/24/2014)... 2014 In June 2014, 15 injured ... bicycles, hand cycles and recumbent bicycles nearly 800 miles ... CanAm Veterans’ Challenge . “Capital to Capital,” the ... about this inspiring ride, is now available through multiple ... color photographs taken during the two-week ride, the 92 ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... vaccine that U.S. officials are preparing to test in West ... vaccine produced a safe and potent immune response in Africans. ... more than 100 Ugandans in 2009 and 2010, prompted the ... protect a person against infection by Ebola, said study author ...
(Date:12/24/2014)... TUESDAY, Dec. 23, 2014 (HealthDay News) -- Longer and colder ... newborns who have brain damage from a lack of oxygen, ... disability in newborns with this condition -- called hypoxic ischemic ... to 33.5 degrees Celsius (92.3 Fahrenheit) for 72 hours, experts ... protects the brains of animals, so this study examined if ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
Other TagsOther Tags